Immunomedics Awarded Additional Intellectual Property

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Immunomedics Awarded Additional Intellectual Property Protection for IMMU-140, an Antibody-Drug Conjugate With Dual-Therapeutic Potential

MORRIS PLAINS, N.J., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq: IMMU ) today announced the issuance of U.S. Patent 9,522,959 for additional claims under the patent family, “Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity.”

The issued patent provides additional coverage for IMMU-140, the third antibody-drug conjugate (ADC) based on the Company’s award-winning SN-38 platform technology. The lead investigational product from that program is sacituzumab govitecan (IMMU-132), which has continued to produce encouraging results in a Phase 2 study in patients with metastatic triple-negative breast cancer (TNBC), and has been designated a Breakthrough Therapy by the FDA for TNBC patients who have received at least two prior therapies for their late-stage disease.

Dr. David M. Goldenberg, Chairman, Chief Scientific Officer and Chief Patent Officer, stated, “IMMU-140 is our newest investigational product built on the same ADC platform used in IMMU-132, and creates the promise of a potential new treatment alternative for cancer patients and new value for our shareholders. We believe IMMU-140 provides an added benefit as a dual-therapeutic and are pleased to receive this new patent. The dual-therapeutic potential of IMMU-140 warrants its clinical development in a range of HLA-DR-positive hematopoietic and solid cancers.”

Dr. Goldenberg added, “The progress that has been made with IMMU-140 underscores Immunomedics’ commitment to executing on its strategy. The attainment of this milestone is the result of years of dedication and hard work by our talented team, and we are committed to continuing this positive momentum. As always, we remained focus on achieving our additional upcoming milestones, which we expect will create additional benefits for patients and Immunomedics’ stockholders.”

The allowed claims in the new patent, which will expire in July 2033, protect the use of IMMU-140 in HLA-DR-expressing B-cell lymphoma, B-cell leukemia, skin, esophageal, stomach, colon, rectal, pancreatic, lung, breast, ovarian, bladder, endometrial, cervical, testicular, melanoma, kidney, or liver cancer. IMMU-140 is comprised of the humanized anti-HLA-DR antibody, IMMU-114, conjugated to SN-38, through the Company’s proprietary linker, CL2A. Thus, this ADC has dual activity, combining the signaling functions of the parental antibody, IMMU-114, with the cytotoxicity of SN-38. Further, the IMMU-140 product candidate builds on the safety and efficacy of its parental antibody, IMMU-114, being studied clinically in patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), where results to-date with a subcutaneous therapy of IMMU-114 are showing promising activity in refractory/relapsed patients, and with a relatively safe profile.

In a preclinical study presented at the 2016 Annual Meeting of the American Society of Hematology, IMMU-140 was shown to have higher potency than naked IMMU-114 in acute lymphocytic leukemia (ALL) and acute myelocytic leukemia (AML), and an added, if not significant, survival benefit in experimental multiple myeloma (MM) and CLL. Importantly, it did not produce any undue toxicity in these four animal models of human blood cancers.

As previously announced, Immunomedics is focused on achieving a number of critical milestones in the near-term including:

  • Preparing to submit a Biological License Application (BLA) to the FDA for accelerated approval for IMMU-132 for patients with metastatic TNBC in mid-2017;
  • Nearing completion of enrolling 100 TNBC patients into the ongoing Phase 2 clinical trial of IMMU-132 by year-end 2016;
  • Presenting interim results of Phase 2 clinical trials of IMMU-132 for patients with urinary bladder cancer at the ASCO symposium on genitourinary cancers to be held in early 2017;
  • Continuing preclinical development of the new ADC, IMMU-140, as a therapeutic for five different blood cancers (NHL, CLL, ALL, AML, MM); poster presented at 2016 meeting of American Society of Hematology (ASH);
  • Pursuing licensing and other strategic activities with regard to IMMU-132 and other clinical and preclinical pipeline drug development candidates, as well as platform technologies, with the support of Greenhill & Co. as its financial advisor;
  • Initiation of Phase 3 Confirmatory Trial in TNBC during early 2017;
  • Potential for Breakthrough Therapy Designation in small-cell and non-small-cell lung, and urinary bladder cancers; and
  • Once IMMU-132 is partnered, the Company could then advance many other preclinical assets into clinical development and even other licensing arrangements; licensing discussions involving some of these other assets are in fact ongoing.

About Immunomedics Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics’ advanced proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, Immunomedics has built a pipeline of eight clinical-stage product candidates. Immunomedics’ portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxic effects that are usually found with conventional administration of these chemotherapeutic agents. Immunomedics’ most advanced ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase 2 trials for a number of solid tumors and metastatic colorectal cancer, respectively. IMMU-132 has received Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer who have failed at least two prior therapies for metastatic disease. Immunomedics has a research collaboration with Bayer to study epratuzumab as a thorium-227-labeled antibody. Immunomedics has other ongoing collaborations in oncology with independent cancer study groups. The IntreALL Inter-European study group is conducting a large, randomized Phase 3 trial combining epratuzumab with chemotherapy in children with relapsed acute lymphoblastic leukemia at clinical sites in Australia, Europe, and Israel. Immunomedics also has a number of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various stages of clinical and preclinical development. These include combination therapies involving its antibody-drug conjugates, bispecific antibodies targeting cancers and infectious diseases as T-cell redirecting immunotherapies, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies, created using its patented DOCK-AND-LOCK® protein conjugation technology. The Company believes that its portfolio of intellectual property, which includes approximately 304 active patents in the United States and more than 400 foreign patents, protects its product candidates and technologies. For additional information on the Company, please visit its website at www.immunomedics.com . The information on its website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials (including the funding therefor, anticipated patient enrollment, trial outcomes, timing or associated costs), regulatory applications and related timelines, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, the Company’s dependence on business collaborations or availability of required financing from capital markets, or other sources on acceptable terms, if at all, in order to further develop our products and finance our operations, new product development (including clinical trials outcome and regulatory requirements/actions), the risk that we or any of our collaborators may be unable to secure regulatory approval of and market our drug candidates, risks associated with the outcome of pending litigation and competitive risks to marketed products, and the Company’s ability to repay its outstanding indebtedness, if and when required, as well as the risks discussed in the Company’s filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

For More Information: Dr. Chau Cheng Senior Director, Investor Relations & Corporate Secretary (973) 605-8200, extension 123 ccheng@immunomedics.com Media Dan Katcher / Ed Trissel / Nick Lamplough Joele Frank, Wilkinson Brimmer Katcher (212) 355-4449 Investors Dan Burch/Bob Marese MacKenzie Partners, Inc. (212) 929-5500

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AWK Adds Fayette Water System With $9M Upgrade Plan

Updated Category News Views 101

Small water systems do not usually collapse in one dramatic heap; they get worn down by scattered pipes, compliance demands, thin staffing and bills nobody wants to raise. That is the backdrop for Pennsylvania American Water’s completed $32.8 million purchase of the Indian Creek Valley Water Authority system. For American Water shareholders, this is the familiar...

Continue Reading
Panama City Beach Rentals: Rules Before the Ocean View

Updated Category News Views 49

A postcard-perfect balcony can hide a remarkably expensive rulebook. That is the unglamorous message in Angie Outlaw’s discussion of vacation-property buying in Panama City Beach: the view may sell the unit, but zoning, association documents, insurance and lender terms determine whether the purchase behaves anything like the income-producing asset a buyer pictured. I...

Continue Reading
JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 63

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
Radiology Staffing Gap Deepens as Imaging Demand Rises

Updated Category News Views 91

An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...

Continue Reading
Scenthound’s Franchise Award Spotlights a Real Test

Updated Category News Views 92

A clean dog may not sound like a growth story, yet Scenthound has turned that neglected chore into a surprisingly serious franchise proposition. The company has won the International Franchise Association’s Emerging Franchisor Award after building its dog-hygiene concept from a 2015 founding into a network with more than 180 open locations. That is a respectable piece...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 177

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading
The Hanover Survey Puts Small-Business Trust on Trial

Updated Category News Views 121

A dark storefront can apparently erase goodwill faster than plenty of owners want to admit. The Hanover Insurance Group's 2026 Small Business Pulse Report found that 60% of surveyed consumers would temporarily buy from a competitor if their preferred small business shut unexpectedly. More than half would start looking elsewhere within a week. That is not a cute...

Continue Reading
Sinopec’s Algerian Outreach Reveals a Patient Long Game

Updated Category News Views 95

Soft Power Does Not Run a Refinery, but It Matters A short video contest in Algiers will not move an oilfield schedule or settle a hydrocarbons negotiation. That is precisely why this Sinopec-backed event deserves a sober look rather than a chest-thumping one. On Nov. 15, Sinopec Group and the Chinese Embassy in Algeria co-hosted the final of their second youth cultural...

Continue Reading
Hyster-Yale's $125 Million Convertible Debt Shuffle

Updated Category News Views 108

Forklifts do not make headlines often, but debt terms sure can. Hyster-Yale has proposed a $125 million private offering of convertible senior notes due November 15, 2031, with buyers able to take another $18.75 million if the initial purchasers exercise their option. For NYSE:HY holders, this is not a victory lap or a distress flare by itself. It is a refinancing...

Continue Reading
Highway 99 Truck Death Puts Safety Records in Focus

Updated Category News Views 60

A stopped car on a highway shoulder is supposed to be a bad day, not a death sentence. Yet on November 5, 2026, a person helping a relative with a disabled vehicle was killed on northbound Highway 99 in Elk Grove after a commercial tractor-trailer allegedly drifted onto the shoulder, hit both stationary vehicles, and overturned. Northbound lanes were closed for hours. A...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Work Protective Gear to Enhance Safety and Comfort

Updated Category News Views 209

Revolutionizing Workplace Safety with New Gear Workplace injuries remain a significant concern across various job sites, with issues such as severe cuts and long-lasting knee damage becoming all too common. These challenges not only compromise the well-being of workers but also inflate costs for employers. Many workers often overlook critical personal protective equipment...

Continue Reading
Exploring Innovations in Toxicology at Upcoming ACMT Meeting

Updated Category News Views 380

Innovative Toxicology Research Unveiled at the 2025 ACMT Meeting In an exciting announcement, the American College of Medical Toxicology (ACMT) is gearing up for its 2025 Annual Scientific Meeting and Symposia, set to take place from April 2 to 6 at the Fairmont Hotel in Vancouver. This year promises an inspiring lineup featuring five days filled with groundbreaking...

Continue Reading
ConnectM Technology Solutions' Live Investor Webinar Invitation

Updated Category News Views 77

ConnectM Announces Exclusive Investor Webinar ConnectM Technology Solutions, Inc. (NASDAQ: CNTM), a pioneering technology firm in the electrification economy, is hosting a special investor webinar on March 4, at 4:15 p.m. Eastern Time. This event is a unique opportunity to learn about the company's strategies and insights in a rapidly evolving industry. Discover the...

Continue Reading
Deadline for SelectQuote Investors Approaching Soon

Updated Category News Views 177

Investors Urged to Take Action on SelectQuote Losses Attention investors! If you have experienced financial losses in SelectQuote, now is the time to act. Faruqi & Faruqi, LLP is leading the charge in investigating claims on behalf of investors who may have suffered due to the company's recent developments. Investors are proudly encouraged to reach out if they believe...

Continue Reading
Empowering Girls in Sports: NRPA and Nike's Initiative

Updated Category News Views 486

NRPA and Nike Unite for Gender Equity in Youth Sports The National Recreation and Park Association (NRPA) has joined forces with Nike, highlighting a shared commitment to advancing gender equity in youth sports. This partnership emphasizes the necessity of equitable access to sporting opportunities for all youth, especially girls, to ensure they thrive in their...

Continue Reading